← Leaderboards
Xin Ge
University Of California Riverside
$5,280,099
Attributed
$7,154,161
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2016–25$5M$3.8M$2.5M$1.3M$0
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,154,161 · 6
By mechanism
R01$2,265,494 · 2
UG3$2,079,796 · 1
R35$1,978,988 · 1
R21$829,883 · 2
Top collaborators
- Elda E. Sanchez2 shared
- Akihiko Urayama2 shared
- Jacob Anthony Galan1 shared
- Ru-Rong Ji1 shared
Others in their field
Top investigators on “Monoclonal Antibodies”
- Bambra Strokes · Ppd Development Lp$461,655,950
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$276,346,332
- Lawrence Corey · Fred Hutchinson Cancer Center$271,417,082
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$257,261,947
- Peter B. Gilbert · Fred Hutchinson Cancer Center$190,281,881
- Barton F Haynes · Duke University$125,632,198
Research focus
Monoclonal AntibodiesAntibodiesBindingEngineeringTherapeutic Monoclonal AntibodiesPeptide HydrolasesSpecificityFamilyGenerationsAntibody Binding SitesAntibody LibrariesPublic HealthAntibody InhibitorPainful NeuropathyTechnologySmall Molecule InhibitorPathologyTreatment EfficacyMethodologyMalignant NeoplasmsEpitopesPharmacologic SubstanceHigh Throughput ScreeningTherapeutic Development
Grant awards (16)
Development of MMP-9 inhibitory monoclonal antibodies to relieve neuropathic pain$2,079,796
UG3 · FY2025 · NS · contact PI
Mechanism of ARIA following Anti-Amyloid Immunotherapy$766,133
R01 · FY2025 · AG
Therapeutic Monoclonal Antibodies Inhibiting Proteases of Biomedical Importance$390,000
R35 · FY2025 · GM · contact PI
Therapeutic Monoclonal Antibodies Inhibiting Proteases of Biomedical Importance$390,000
R35 · FY2024 · GM · contact PI
Therapeutic Monoclonal Antibodies Inhibiting Proteases of Biomedical Importance$28,988
R35 · FY2024 · GM · contact PI
Therapeutic Monoclonal Antibodies Inhibiting Proteases of Biomedical Importance$390,000
R35 · FY2023 · GM · contact PI
Therapeutic Monoclonal Antibodies Inhibiting Proteases of Biomedical Importance$390,000
R35 · FY2022 · GM · contact PI
Rational Structure-Based Design of Broad Neutralizing Humanized svMP mAbs$183,948
R21 · FY2022 · AI
Protease Activated Bi-Specific Antibody Prodrugs for Efficient Transportation Across Blood-Brain Barrier$429,000
R21 · FY2021 · NS · contact PI
Therapeutic Monoclonal Antibodies Inhibiting Proteases of Biomedical Importance$390,000
R35 · FY2021 · GM · contact PI
Rational Structure-Based Design of Broad Neutralizing Humanized svMP mAbs$216,935
R21 · FY2021 · AI
Structure-based design of camel-like human selective mAbs against MMPs in disease$294,763
R01 · FY2020 · GM · contact PI
Structure-based design of camel-like human selective mAbs against MMPs in disease$294,765
R01 · FY2019 · GM · contact PI
Structure-based design of camel-like human selective mAbs against MMPs in disease$297,160
R01 · FY2018 · GM · contact PI
Structure-based design of camel-like human selective mAbs against MMPs in disease$298,650
R01 · FY2017 · GM · contact PI
Structure-based design of camel-like human selective mAbs against MMPs in disease$314,023
R01 · FY2016 · GM · contact PI